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Telomeres are dynamic DNA–protein complexes at the end of linear chromosomes. Maintenance of functional telomeres is required for
chromosome stability, and to avoid the activation of DNA damage response pathway and cell cycle arrest. Telomere-binding proteins play crucial
roles in the maintenance of functional telomeres. In this study, we employed affinity pull-down and proteomic approach to search for novel
proteins that interact with the single-stranded telomeric DNA. The proteins identified by two-dimensional gel electrophoresis were further
characterized by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) and MALDI-TOF-TOF tandem
MS. Among the five identified proteins, we report here the biochemical properties of a novel protein, hnRNP A3. The purified hnRNPA3 bound
specifically to G-rich strand, but not to C-rich strand or double-stranded telomeric DNA. The RRM1 (RNA recognition motif 1) domain, but not
RRM2, of hnRNPA3 is sufficient to confer specific binding to the telomeric sequence. In addition, we present evidence that hnRNPA3 can inhibit
telomerase extension in vitro. These biochemical properties of hnRNP A3 suggest that hnRNP A3 can participate in telomere regulation in vivo.
© 2007 Elsevier B.V. All rights reserved.Keywords: Telomere; Telomerase; hnRNP A3; Telomere-binding protein; RNA recognition motif1. Introduction
Telomeres are specialized structures at the ends of chromo-
somes. Human telomeric DNA consists of several thousands of
tandem-repeated sequences with a short single-stranded over-
hang on the 3′ G-rich strand. A complex formed with six
telomere-specific proteins, which include POT1, TRF1, TRF2,
Rap1, TIN2 and TPP1 [1,2], associates with the terminal region
to provide a protective cap and allows cells to distinguish
telomeres from DNA breaks [3–5]. Although the precise
structure of telomeres in vivo is not known, it has been suggested
that telomeres may exist as dynamic structures between capped
or uncapped states [6,7]. An uncapped telomere may contain a 3′
overhang of G-rich strand. On the other hand, a t-looped
structure of telomere has been observed in vitro and from chro-Abbreviations: MALDI-TOF, matrix-assisted laser desorption ionization
time-of-flight; MS, mass spectrometry; hnRNP, heterogeneous nuclear ribonu-
cleoprotein; RRM, RNA recognition motif
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doi:10.1016/j.bbamcr.2007.08.006matin isolated from human andmouse cells [8], and is postulated
to serve as the capped structure that protects telomere fromDNA
degradation and unwanted recombination.
Functional telomeres play an important role in cellular
senescence [4,7,9]. Dysfunctional telomeres are known to
trigger growth arrest, senescence, apoptosis, and an increase of
end-to-end fusions and anaphase bridges [4,7]. Dysfunctional
telomeres may be produced via various mechanisms. Telomere
attrition represents a normal mechanism that limits the
replicative potential of human somatic cells and can serve as
a tumor suppressor pathway for potential cancer cells. The
gradual loss of telomeric DNA with each round of DNA
replication depletes the telomere reserve and leads to a growth
arrest that is accompanied by senescence or apoptosis, a process
known as replicative senescence. Telomere dysfunction can also
occur due to loss or mutation of telomere-binding proteins. Loss
of TRF1 or TRF2 function had been shown to lead to
chromosomal abnormalities, cell cycle arrest, and the activation
of DNA damage response pathway [7,10].
The most versatile and widely used method of telomere
lengthmaintenance is based on telomerase. Human telomerase is
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synthesis of telomeric repeats (TTAGGG) at 3′ ends of the G-
rich strand [11]. Normal human somatic cells undergo telomere
attrition because of inadequate level of telomerase. In contrast,
a majority of immortal and cancer cells have an indefinite
proliferative capacity and maintain their telomere length by
upregulating telomerase [12,13]. While the regulated telomerase
expression may serve as the primary control of telomere length
maintenance, the synthesis of telomeric DNA by telomerase is
anticipated to be affected by many factors such as the
recruitment of telomerase to the telomere terminus, the initiation
of elongation, and/or the processivity of the elongation cycles.
Therefore, telomere length is influenced by the level of telo-
merase expression but also depends on control pathways that act
on recruitment of telomerase and/or in cis at each individual
telomere. Indeed, telomere-binding proteins and telomerase-
interacting proteins have been demonstrated to participate in
telomere length homeostasis [10,14,15].
In view of the important role of telomere-binding proteins in
the telomere functions, we have employed affinity purification
protocol and proteomic approach to search for novel proteins
that bind to G-rich strand of telomeric DNA. Here, we report
our biochemical studies of a newly identified telomere-binding
protein, hnRNP A3. Based on the biochemical properties ofFig. 1. Two-dimensional gel electrophoresis of proteins that bind to single-stranded t
biotinylated G-3S (panel B). Proteins that bound to the oligonucleotides were first ele
by electrophoresis in a 12% SDS-PAGE. The proteins were identified by silver sta
proteins and were further analyzed by MALDI-TOF MS.purified hnRNP A3 in vitro, we suggest that this protein can
participate in telomere length maintenance in vivo.
2. Materials and methods
2.1. Chemicals, enzymes, oligonucleotides, and antibodies
Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum,
Superscript III reverse transcriptase, TRIzol reagent, and antibiotics were from
Gibco-BRL. RNase inhibitor was purchased from CalBiochem Co. Taq DNA
polymerase was from Abgene, Epsom, UK. Polyclonal antibody against hnRNP
A3 was prepared by Genesis Biotech. Inc. using oligopeptide VKPPPGRPQPD-
SFRC. Gel electrophoresis reagents were fromBio-Rad. All other chemicals were
fromSigmaChemical Co. The biotinylated and non-biotinylated oligonucleotides
G-1 (GCCAAGGAGCCATTAGGG), G-2 (GCCAAGTTAGGGTTAGGG), G-3
(TTAGGGTTAGGGTTAGGG), G-4 (TTAGGGTTAGGGTTAGGGTTAGGG),
C-3 (CCCTAACCCTAACCCTAA), G-3S (TAGTGGAGTTGGTGTGAG), and
NS (GCCAAGGAGCCATGAGTG) were purchased from Bio Basic Inc.
(Ontario, Canada). Double-strand telomeric DNA (dsG/C) was constructed by
annealingG-3 and C-3. Other oligonucleotides were obtained fromBioBasic Inc.
2.2. Cell culture
Nasopharyngeal carcinoma-derived cell line NPC-TW02 (formally named
NPC-076 in reference [16]) was routinely cultured in DMEM supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 U/ml
streptomycin and 0.25 μg/ml amphotericin B, and used as a convenient sourceelomeric DNA. Nuclear proteins were mixed with biotinylated G-3 (panel A) or
ctro-focused in a pH 6–11 gradient, and then separated in the second dimension
ining. The numbered protein spots in panel A were putative telomere-binding
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incubator containing 5% CO2.
2.3. Nuclear extracts
Cells were suspended in NEBA buffer (10 mM HEPES, pH 7.9, 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF), and NP-40
was added to a final concentration of 0.6%. After vortexing for 10 min, the
disrupted cells were centrifuged at 14,000 rpm for 1 min. The pellets were
resuspended in 50 μl of AFB A 300 (20 mM HEPES, pH 7.9, 300 mM KCl,
1 mM EDTA, 10% glycerol, 0.5 mM DTT, 0.5 mM PMSF) and vortexed for
15 min at 4 °C. After centrifugation for 5 min at 14,000 rpm, the supernatants
were collected and used as nuclear extracts. The protein concentrations were
determined using Coomassie protein assay reagent (Bio-Rad).
2.4. Affinity purification of telomere-binding proteins
The general protocol for affinity purification followed that described by
Schnapp et al. [17]. In brief, nuclear extracts (5 mg/ml) were mixed with
biotinylated G-3 or G-3S in AFBA300 buffer containing 0.5% Triton X-100 and
50 μg/ml yeast tRNA. After incubating at 30 °C for 5 min, samples were mixed
with pre-blocked NeutrAvidin beads (UltraLink Immobilized NeutrAvidin Plus,Table 1
Identification of proteins that bind to telomeric DNA
Spot Identify of protein Mass PI
1 Unidentified
2 hnRNP A2/B1 36041/37464 8.67/8
3 hnRNP A3 39779 9.1
4 hnRNP A2/B1 36041/37464 8.67/8
5 hnRNP A2/B1 36041/37464 8.67/8
6 hnRNP A2/B1 36041/37464 8.67/8
7 SYNCRIP protein 46410 8.94
8 Unidentified
9 Unidentified
10 Carcinoma-associated Ag 35564 7.42
11 hnRNP A3 39779 9.1
12 hnRNP A3 39779 9.1
13 hnRNP A3 39779 9.1
14 hnRNP A2/B1 36041/37464 8.67/8
15 hnRNP A2/B1 36041/37464 8.67/8
16 hnRNP A2/B1 36041/37464 8.67/8
17 hnRNP A2/B1 36041/37464 8.67/8
18 hnRNP A2/B1 36041/37464 8.67/8
19 hnRNP A2/B1 36041/37464 8.67/8
20 hnRNP A2/B1 36041/37464 8.67/8
21 hnRNP A2/B1 36041/37464 8.67/8
22 hnRNP A2/B1 36041/37464 8.67/8
23 hnRNP A2/B1 36041/37464 8.67/8
24 hnRNP A2/B1 36041/37464 8.67/8
25 hnRNP A2/B1 36041/37464 8.67/8
26 hnRNP A1 38805 9.26
27 hnRNP A1 38805 9.26
28 hnRNP A1 38805 9.26
29 hnRNP A1 34245 9.27
30 hnRNP A1 34245 9.27
31 hnRNP A1 34245 9.27
32 hnRNP A1 34245 9.27
33 hnRNP A1 34245 9.27
34 hnRNP A1 34245 9.27
35 hnRNP A1 34245 9.27
36 hnRNP A2/B1 36041/37464 8.67/8
37 hnRNP A2/B1 36041/37464 8.67/8
38 hnRNP A2/B1 36041/37464 8.67/8
39 hnRNP A2/B1 36041/37464 8.67/8PIERCE). After washing three times with AFB A300 containing 0.5% Triton X-
100 and two timeswith AFBA300, samples were suspended in 100μl of 2D lysis
buffer (8M urea, 4%CHAPS, 40mMTris base) to dissolve the proteins bound to
the beads.
2.5. Separation of proteins by two-dimensional electrophoresis
The proteins bound to the affinity oligonucleotides were placed in a pH 6–11
immobilized non-linear gradient (IPG) strip (Amersham Biosciences). The
proteins in the IPG strip were isoelectrically focused as follows: 30 V, 12 h; 50 V,
0.5 h; 100 V, 0.5 h; 250 V, 0.5 h; 500 V, 0.5 h; 1000 V, 0.5 h; 4000 V, 0.5 h; and
8000 V, 48 h. After focusing, the IPG strip was immersed in a TG buffer [50 mM
Tris–Cl, pH 8.8, 6 M urea, 30% glycerol (v/v), 2% SDS (w/v), 0.002% bromo-
phenol blue] containing 2% DTT for 15 min, and then in TG buffer containing
2.5% iodoacetamide for 15 min. The buffer-balanced IPG strip was then placed
onto a 10% SDS-polyacrylamide gel and electrophoresed with a constant 30mA/
gel for 3.5 h. The proteins on the gel were identified by silver staining.
2.6. Analysis of proteins by MALDI-TOF MS
The sliced gels containing the desired protein were washed with water and
50 mM NH4HCO3/acetonitrile (1:1), destained with a solution containing 6 mMCoverage (%) Accession no. Score
.97 AAB60650/B34504 95/92
23 Q6URK 57
.97 43/41 AAB60650/B34504 95/62
.97 54/52 AAB60650/B34504 182/175
.97 49/48 AAB60650/B34504 137/33
23 AAH40844 48
25 B48149 40
34 Q6URK 79
26 Q6URK 61
29 Q6URK 52
.97 62/60 AAB60650/B34504 213/208
.97 48/47 AAB60650/B34504 100/96
.97 51/50 AAB60650/B34504 228/233
.97 43/42 AAB60650/B34504 83/80
.97 50/49 AAB60650/B34504 86/83
.97 41/49 AAB60650/B34504 242/235
.97 70/67 AAB60650/B34504 219/208
.97 41/49 AAB60650/B34504 140/154
.97 48/46 AAB60650/B34504 96/93
.97 64/63 AAB60650/B34504 247/240
.97 71/71 AAB60650/B34504 248/254
.97 53/54 AAB60650/B34504 161/169
33 ROA1_HUMAN 52
60 ROA1_HUMAN 202
34 ROA1_HUMAN 60
61 S02061 158
54 S02061 115
43 S02061 66
37 S02061 54
61 S02061 142
61 S02061 163
54 S02061 79
.97 46/48 AAB60650/B34504 95/102
.97 47/45 AAB60650/B34504 102/99
.97 35/37 AAB60650/B34504 66/72
.97 48/50 AAB60650/B34504 99/105
Fig. 2. Analysis of Spot 11 protein by MALDI-TOF spectrometry. The protein of Spot 11 in Fig. 1 was in-gel digested, and analyzed by MALDI-TOF spectrometry.
The spectrum of peptides with different m/z is shown in panel A. The sequence of peptides (panel B) was deduced by searching MSDB database. The sequences that
match human hnRNPA3 are shown as bold characters in panel C. The peptide with m/z 1882.93 was further analyzed by TOF–TOF and the deduced peptide is shown
as underlined in panel C.
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25 mM NH4HCO3. After becoming transparent, the gels were treated with
acetonitrile before digesting with trypsin (10 μg/ml) at 37 °C for 12 h. The
digested peptides in acetonitrile containing 0.5% trifluoroacetic acid were
spotted on the sample tray, dried, and mixed with 0.2 μl matrix α-cyano-4-
hydroxy cinnamic acid. The samples were analyzed on Ultraflex MALDI-TOF/
TOF MS (Bruker Daltonics, Germany). The software Biotool was used to
analyze the spectrums obtained.Fig. 3. Western blot analysis of the pull-down proteins. Nuclear proteins were mixed w
hnRNP A3 and hnRNP A2/B1 in the supernatant (Sup) or pellet (Pellet) was analyz2.7. DNA cloning
Total mRNAswere extracted by TRIzol andwere reverse transcribed (RT) by
reverse transcriptase to generate cDNAs. For the cloning of hnRNP A3, the
primers 5′-AACCATATGGAGGTAAAACCGCCGC-3′ and 5′-CTGGGATTC-
TTAGAACCTTCTGCTACCATATCCAC-3′were used to amplify the cDNAby
polymerase chain reaction (PCR). The conditions for RT-PCR were similar to
those described earlier [16]. The DNA products of RT-PCR were purified andith biotinylated G-3, G-3S, C-3, NS, ds G/C or beads alone, and the presence of
ed by Western blot.
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the manufacturer's suggestions. After transforming into Escherichia coli DH5α
cells, recombinant clones (pGEM-T/hnRNP A3) were obtained, and confirmed
by restriction enzyme analysis and DNA sequencing. Subcloning of hnRNPA3
onto bacterial expression vector pET-15b (Novagen)was achieved by ligating the
NdeI/BamHI digested DNA fragments from pGEM-T/hnRNP A3 to the NdeI/
BamHI digested pET-15b DNA, and transforming into E. coli DH5α cells.
Cloning of the RRM1 (RNA recognitionmotif 1), RRM2or RRM(1+2) domains
of hnRNPA3 (see Fig. 4) was done by first cloning the desired DNA fragments
into the pGEM-T vector and then subcloned onto the pET-15b as described
above. The sets of primers used for the PCR amplification of the desired
DNA fragments using pGEM-T/hnRNP A3 DNA as the template were M1-F
(5′-AACCATATGGAGGTAAAACCGCCGCCGC-3′) and M1-R (5′-CTGGG-
ATCCTTAACCAGGCTTTACAGAATC-3′) for RRM1; M2-F (5′-ACGCA-
TATGGCCCATCTAACAGTGA-3′) and M2-R (5′-CTGGGATCC-
TTAACGACCTCTCTGTGATCC-3′) for RRM2; and M1-F and M2-R for
RRM(1+2).
2.8. Expression and purification of hnRNP A3 and its derivatives
The recombinant plasmids were transformed into E. coli strain BL21(DE3)
pLysS. Following the induction with IPTG, the His-tagged proteins were
purified through nickel column as described [18]. Western blot analysis was
performed as previously described [16].
2.9. DNA-binding and telomerase assays
The DNA-binding activity of the purified proteins was assayed by both
EMSA (electrophoresis mobility shift assay) and affinity pull-down methods. In
the EMSA, biotinylated oligonucleotides were reacted with the purified proteins
at 24 °C for 30 min in a buffer containing 10 mM Tris, pH 7.5, 50 mM KCl,
1 mM DTT, 2.5% glycerol, 5 mMMgCl2, 50 ng/μl poly(dI:dC), and 0.05% NP-
40. The reaction mixtures were electrophoresed in a native polyacrylamide gel,
and then transferred to immobilon-NY+membrane (Millipore). Detection of
biotinylated DNA in the membrane was done with LightShift Chemiluminescent
EMSA kit (Pierce Co.) by following the manufacturer's suggestions. In the
affinity pull-down assay, recombinant protein (5 μg) was reacted with 0.1 nmol
biotinylated DNA at 30 °C for 5 min in AFB A300 containing 0.5% Triton X-
100 and 10 μg/ml yeast tRNA. The proteins bound to the affinity DNA were
pulled down by NeutrAvidin beads as described above in the section for Affinity
purification of telomere-binding proteins. Telomerase was assayed by telomeric
repeat amplification protocol (TRAP) as described previously [19].Fig. 4. Schematic presentation of the cloned derivatives of hnRNPA3 (panel A)
and the purified proteins from these derivatives (panel B). In panel A, the
various regions of hnRNP A3 that were cloned onto the expression plasmids
were schematically depicted. The proteins expressed by these plasmids were
purified by nickel column and separated in a 12% polyacrylamide gel containing
SDS (SDS-PAGE). The proteins in the SDS-PAGE were identified by staining
with Coomassie brilliant blue (left in panel B) or by Western blot with antibody
against His-tag (right in panel B). The molecular mass markers (M) with the
indicated mass in kilodaltons are shown in the left margin.3. Results
3.1. Identification of proteins that bind to single-strand G-rich
telomeric DNA
The proteins that bound specifically to telomeric DNAwere
isolated by affinity purification using biotinylated G-3 as the
affinity probe. In our initial trials, the isolated proteins were
separated by 2D gel electrophoresis using a pH 3–10 IPG strip
in the first dimension and 8% SDS-polyacrylamide gel in the
second dimension. We observed that there were many poorly
separated telomere-binding proteins with an expected pI around
pH 8–9 and Mr around 35–45 kDa (data not shown). To
improve the separation of these proteins, we have modified our
2D protocol using a pH 6–11 IPG strip in the first dimension
and a 12% SDS-polyacrylamide gel in the second dimension.
Representative results were shown in Fig. 1. The protein spots
that were detected only from the biotinylated G-3 were
marked. After in-gel digestion with trypsin, the peptides from
these protein spots were analyzed by MALDI-TOF MS. Theputative identities of these proteins are summarized in Table 1.
Out of the total 39 protein spots analyzed, no identity can be
assigned to 3 spots (#1, 8, 9). The proteins in Spots 2, 4–6, 14–
25, 36–39 were assigned as hnRNPA2/B1; the proteins in Spots
26–35 were assigned as hnRNPA1; the proteins in Spots 3, 11–
13 were assigned as hnRNPA3; and the proteins in Spot 7 and 10
were assigned as carcinoma associated antigen and SYNCRIP,
respectively. The hnRNP A2/B1 and hnRNP A1 had been
previously reported to bind G-rich telomeric DNA [20,21].
3.2. Confirmation of the identity for hnRNP A3
Analysis of the MALDI-TOF MS spectrum for Spot 11 in
Fig. 1 revealed that the peptides could match 34% of human
hnRNP A3 (Fig. 2A–C). To confirm the assigned identify of
hnRNPA3, the peptide with m/z 1882.93 in Fig. 2Awas further
analyzed by TOF–TOF and the deduced peptide sequence
(DTEEYNLR) that corresponds to hnRNPA3 was underlined in
Fig. 2C. Based on these results, we confidently assigned the
protein in Spot 11 as hnRNPA3. Finally, to confirm that hnRNP
A3 is indeed specifically pulled down by the biotinylated G-3,
biotinylated G-3, G-3S, C-3, NS, and ds G/C were employed as
the affinity oligonucleotides in the pull-down assay, and the
presence of hnRNP A3 and hnRNP A2/B1 in the supernatant
(Sup) or pellet (Pellet) was analyzed by Western blot. As shown
in Fig. 3, hnRNPA3 and hnRNPA2/B1 were selectively pulled
down by the biotinylated G-3 but not by the G-3S, C-3, NS, or
ds G/C.
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and its derivatives
To investigate the DNA-binding properties of hnRNPA3, we
have employed RT-PCR to clone the cDNA of hnRNP A3 into
bacterial expression vector pET-15b (pET-15b/hnRNP A3).
Despite that the initial pET-15b/hnRNP A3 contains the full-
length cDNA of hnRNP A3, stable clones derived from the
propagation of this plasmid in BL21(DE3)pLysS cells
invariably were deleted in nucleotides 735–974. Therefore,
the proteins isolated from the overexpression of this plasmid
in BL21(DE3)pLysS cells were deleted for amino acids 245–
335, which we named dA3 (Fig. 4A). The relative molecular
mass (Mr) of purified dA3, RRM1, RRM2 and RRM(1+2),
shown in Fig. 4B, was in agreement with the predicted
values.Fig. 5. DNA-binding activities of purified dA3. (A) Purified dA3 was mixed with bio
Western blot using antibody against His-tag. (B) Biotinylated G-3 was incubated wi
labeled G-3 or G-3S. The DNA-binding activity of dA3 was assayed by EMSA. (C
substrates: G-3, G-3S, C-3, TS and dsG/C. (D) The length of telomeric repeat require
containing one to four TTAGGG repeats (G-1, G-2, G-3 or G-4).To address if dA3 possesses the telomere-specific DNA-
binding activity, purified dA3 was first mixed with biotinylated
G-3, and assayed by EMSA and pull-down method. As shown
in Fig. 5A, dA3 could be pulled down by G-3, but not by G-3S.
Incubation of biotinylated G-3 with increasing concentration
of dA3 produced slowing moving complexes which could be
competed by unlabeled G-3, but not by G-3S competitor
(Fig. 5B). These results indicate that dA3 can bind directly to G-
3 but not to G-3S. Next, the substrate specificity of dA3 was
examined using EMSA. As shown in Fig. 5C, dA3 could only
bind to G-rich single-strand DNA, but not C-rich strand,
double-stranded telomeric DNA, or TS. Finally, we addressed
what is the minimal telomeric repeat length that is required for
the observed DNA binding by dA3. As shown in Fig. 5D, dA3
could bind to single-strand DNA containing two or more repeats
of TTAGGG, but not to G-1 or NS.tinylated G-3 or biotinylated G-3S, and the pull-down proteins were analyzed by
th different concentrations of dA3 in the absence or presence of excessive non-
) Substrate specificity of dA3 was assayed by EMSA with the following DNA
d for the binding of dA3 was assayed by EMSAwith non-binding sequence (NS)
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hnRNP A3
To address which functional domain is responsible for the
observed binding to G-rich DNA by dA3, we analyzed the
DNA-binding activity of RRM1, RRM2 and RRM(1+2) using
both EMSA and pull-down method. As shown in Fig. 6A,
RRM2 could not be pulled down by either G-3 or G-3S, while
both RRM1 and RRM(1+2) could be pulled down by G-3.
However, weak but detectable amount of RRM1 and RRM(1+
2) was present in the pellets pulled down by G-3S. Incubation
of biotinylated G-3 with increasing concentration of RRM1 or
RRM(1+2), but not RRM2, produced slowing moving
complexes (Fig. 6B and C). Although the mobility shift
requires a higher concentrations of RRM1 as compared with
RRM(1+2) or dA3 (Fig. 5B), these results, nonetheless,
indicate that RRM1 suffices for the DNA-binding activity of
hnRNP A3.Fig. 6. DNA-binding activity of RRM1, RRM2 and RRM(1+2). The ability of RRM1
method (A) and by EMSA (B and C). The conditions for pull-down assay and EMS3.5. hnRNP A3 inhibits telomerase in vitro
The specific binding of hnRNP A3 to telomeric DNA raises
the question that this protein may affect the synthesis of telo-
meric DNA by telomerase. To address this question, the effects
of hnRNPA3 on the synthesis of telomeric DNAwere examined
in vitro by TRAP. When the dA3 was added to the reaction
mixtures prior to the start of the assay by TRAP, the telomerase
activity was greatly inhibited when the added dA3 was greater
than 0.25–0.5 μM (Fig. 7A). This inhibition of telomerase
activity was also observed by the addition of RRM(1+2) or
RRM1, but not RRM2 (Fig. 7A). The concentrations of RRM
(1+2) and RRM1 required to inhibit telomerase were higher
than that of dA3, which may reflect their relative activity to
bind G-rich telomeric DNA as shown in Figs. 5 and 6.
To determine if the observed inhibition of telomerase activity
may be at the step of PCR amplification, the telomerase in the
nuclear extracts was allowed to synthesize telomeric repeats for, RRM2 and RRM(1+2) to bind telomeric DNA G-3 was assayed by pull-down
A were as described in Materials and methods.
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PCR. As shown in Fig. 7B, delayed addition of dA3 also
eliminated the detection of telomerase activity, indicating that
dA3 interferes with the PCR amplification of the DNA products
synthesized by telomerase. Finally, to determine if dA3 inhibits
the step of extension by telomerase, dA3 was added to the
extension mixtures at 0, 5, 10 or 15 min, and the DNA was
extracted at the end of extension period before performing the
PCR amplification. As shown in Fig. 7C, DNA products that
contain extended telomeric repeats were not detected if dA3 was
added at the start of the extension. However, DNA productsFig. 7. Effects of hnRNPA3 derivatives on the telomerase activity in vitro. (A) Nucle
RRM(1+2) and assayed for telomerase activity by TRAP. (B) Nuclear extracts were in
reaction mixtures. The extended DNA products in the presence of added dA3 were su
Nuclear extracts were incubated with the primer TS for different lengths of time be
reaction mixtures were extracted with phenol before subsequent amplification by PCwith extended telomeric repeats were readily detected if the
addition of dA3 was delayed. Since dA3 did not bind to TS
primer (Fig. 5C), and the lengths of telomeric repeats
synthesized prior to the addition of dA3 appeared to correlate
with the times of delayed addition (Fig. 7C), these results
indicate that dA3 inhibits the extension by telomerase.
4. Discussion
In this work, we have employed affinity purification protocol
combined with MALDI-TOF analyses to identify proteins thatar extracts were mixed with increasing concentrations of dA3, RRM1, RRM2 or
cubated with the primer TS for different lengths of time before adding dA3 to the
bsequently amplified by PCR and resolved in the neutral polyacrylamide gel. (C)
fore adding dA3 to the reaction mixtures. The extended DNA products in the
R. The PCR products were then resolved in the neutral polyacrylamide gel.
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by Ishikawa et al. [22], the majority of the identified proteins are
hnRNPs. Among the five putative proteins identified in this
study, hnRNP A2/B1 and hnRNP A1 had been shown to bind
G-rich telomeric DNA with high specificity [20,21]. HnRNP
A3 was recently identified in the pull-down with a telomeric
oligonucleotide [23], although its specificity to bind telomeric
DNA had not been demonstrated. The other two putative pro-
teins, carcinoma-associated antigen and SYNCRIP, were not
described previously. Surprisingly, other known G-rich strand
telomere-binding proteins, such as Pot1 and hTERT, could not
be identified in the present approach. Presumably, the abun-
dance of hnRNP A1, hnRNP A2/B1, and hnRNP A3 in the
nuclear extracts are far greater than that of Pot1 and hTERT,
thus overshadowing the ability to detect scarce telomere-
binding proteins.
Here we have cloned the cDNA of hnRNPA3 onto bacterial
expression vector to study the biochemical properties of puri-
fied hnRNP A3. Much to our surprise, however, the purified
hnRNP A3 had an apparent molecular mass that was smaller
than the predicted value. Analysis of the DNA sequence in the
stable clones derived from the propagation of pET-15b/hnRNP
A3 in BL21(DE3)pLysS cells revealed that the hnRNPA3 gene
was deleted at nucleotides 735–974. Despite many attempts to
modify the conditions of propagating this plasmid in BL21
(DE3)pLysS cells, we had been unable to obtain intact hnRNP
A3 protein so far. Examination of the region that is deleted in
the stable clones reveals that there are two direct repeats with
high homology at positions 718–734 and 958–974 of the
hnRNPA3 gene. An active recombination between these sites is
likely to account for the observed deletion in this region.
Despite our inability to obtain intact hnRNP A3 for DNA-
binding studies, we have shown that the hnRNP dA3 possesses
the DNA-binding activity which is specific to the G-rich strand,Fig. 8. Amino acid sequence comparison for the RRM1 and RRM2 of hnRNPA1, A
capital letters in the bottom. The amino acids that are conserved in A1 and A3, butbut not to the C-rich strand or double-strand of telomeric DNA
(Fig. 5A–C). The amino acids deleted in the hnRNP dA3 were
in the C-terminal Gly-rich region, which have been reported to
influence the binding affinity of the A/B group of hnRNP
proteins to RNA [24] but not to telomeric DNA [23,25]. Here,
we presented evidence that the RRM1 domain but not the
RRM2 domain of hnRNP A3 is essential for the telomeric
DNA-binding activity. Nonetheless, the RRM2 appears to play
a role in facilitating the DNA binding, since RRM(1+2) had a
greater DNA-binding activity than RRM1 (Fig. 6). The findings
that the RRMs of hnRNP A1 (20), A2/B1 (23) and A3 (Fig. 6)
can bind specifically to telomeric DNA suggest that such a
DNA-binding activity may be common characteristics of
RRM1+RRM2 of A/B groups of hnRNP proteins. However,
our results for the binding of G3 telomeric DNA to individual
RRMs differ from the previous observations with hnRNP A2,
which showed some binding to RRM2 but no binding to RRM1
[23]. In a similar study for the binding of a decameric telomeric
repeat, the RRM1 of hnRNP A1 was shown to display strong
binding, the RRM2 displayed a weaker binding and the RRM
concatamer (UP1) had the strongest association [20]. Therefore,
hnRNP A3 appears to bear more resemblance to hnRNP A1 in
the telomeric DNA binding. A comparison of RRM1 from
hnRNPA1, A2 and A3 have indicated that an identity of 90.3%
between A1 and A3, whereas the identity between A2 and A3
was 77.8% (Fig. 8). There are a total of 9 amino acids that are
conserved in A1 and A3, but not in A2 (underlined in Fig. 8).
One or more of these sites may be potentially critical for the
telomeric DNA-binding activity of RRM1.
It is interesting to note that the major G-rich strand telomere-
binding proteins identified in the nuclear extracts are hnRNPs
([22] and this study). These hnRNPs were originally found to
associate with pre-mRNA and thought to participate in pre-
mRNA processing, alternative splicing, transcriptional regula-2, and A3. The amino acids that are conserved in all hnRNPs are marked with
not in A2, are underlined.
202 P.-R. Huang et al. / Biochimica et Biophysica Acta 1783 (2008) 193–202tion, or mRNA transport [26]. The findings that many of these
hnRNPs bind to G-rich strand telomeric DNA suggest that these
proteins can also participate in telomere function. Although
there is no report that hnRNPs may be a structural component
of telomere, several hnRNPs have been shown to interact
with telomerase, to protect telomeric DNA from nuclease
attack and to affect the synthesis of telomeric repeats in vitro
[14,20,25,27,28]. In fact, a role of hnRNP A1 in telomere
maintenance in vivo has been convincingly documented [29]
and a stimulatory effect of telomerase activity by hnRNPA1 has
been reported [28]. Although the DNA-binding property of
hnRNPA3 is similar to hnRNPA1, our finding for an inhibition
of the telomerase extension by hnRNP dA3 in vitro (Fig. 7)
suggests that hnRNP A3 may function negatively in telomere
maintenance in vivo.
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